https://www.thebodypro.com/author/graeme-moyle

Latest by Graeme Moyle, M.D., M.B., B.S., Dip. G.U.M.

Promo Image
Conference Coverage

ATAZIP: Switching Away From Lopinavir/Ritonavir

Switching between protease inhibitors (PIs) may lead to improved dosing frequency, better management of gastrointestinal and lipid toxicity and a reduction in ritonavir (RTV, Norvir) exposure levels. The SWAN study1 was the largest study to evaluate ...

Promo Image
Conference Coverage

Can HLA-B*5701 Testing Help Avoid Abacavir Hypersensitivity Reaction?

Retrospective analyses of abacavir (ABC, Ziagen)-treated individuals who have experienced hypersensitivity reaction (HSR) have suggested that the majority of these abacavir-related events, at least in white and Thai persons, occur in the presence of ...

Promo Image
Conference Coverage

Cross-Resistance Between Integrase Inhibitors

HIV integrase inhibitors represent a new class of antiretroviral drugs that target a crucial post-transcriptional event in the life cycle of HIV. There is considerable excitement about the potential of this new class of antiretroviral agents to revol...

Promo Image
Conference Coverage

Faster Viral Decay With Raltegravir

The lead agent in the integrase inhibitor drug class, raltegravir (RAL, MK-0518) has demonstrated potent antiretroviral activity in phase 2 and 3 clinical trials conducted in both treatment-naive1 and treatment-experienced individuals2 when combined ...

Promo Image

HIV JournalView

Table of Contents

A Search for Associated Factors and the Potential for Shifting HIV Tropism

Insight Into the Metabolic Effects of PI Versus NNRTI Versus PI + NNRTI Regimens

Darunavir Proves Its Mettle in the Salvage Setting

Valproic Acid Not a P...

Promo Image
News

An Alternative NNRTI, TMC278, Progresses in Development

Listen to Dr. Pozniak'sstudy summary (1.2MB MP3, 3 min.)View study slides

Multiple comparative clinical trials demonstrate that efavirenz (EFV, Sustiva, Stocrin) plus two nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), such as emtri...

Promo Image
Conference Coverage

Phase 3 Results of Two Key Trials of Maraviroc, the First-in-Class CCR5 Antagonist

Maraviroc (MVC, UK-427,857) is the first CCR5 antagonist and the first oral agent with a new mechanism of action to reach phase 3 development since the approval of the first protease inhibitors (PIs) in the late 1990s. During the process of viral ent...

Promo Image
Conference Coverage

The Last Word on Aplaviroc: A CCR5 Antagonist With Poor Efficacy

The development of the CCR5 antagonist aplaviroc (GW873140) by GlaxoSmithKline (Glaxo) was prematurely discontinued due to several cases of treatment-associated hepatotoxicity1 -- mercifully, none fatal. The agent also appears to be associated with d...

Promo Image
Conference Coverage

Switching From Zidovudine/Lamivudine to Tenofovir/Emtricitabine: Results of an Uncontrolled Cohort

The long-term toxicity of zidovudine (AZT, Retrovir) remains an important obstacle for sustained therapy with this drug. Although the initial nausea associated with the commencement of zidovudine-containing therapy usually settles within a matter of ...

Promo Image
Conference Coverage

The GEMINI Study: Are Saquinavir + Ritonavir and Lopinavir/Ritonavir Twins?

We are beginning to see a rash of clinical trials comparing the effectiveness of different boosted protease inhibitors (PIs) as initial therapy. The majority of these studies are comparing alternative boosted PIs with lopinavir/ritonavir (LPV/r, Kale...